Atlanta, GA, July 22, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that it will report second quarter 2025 financial results on Monday, July 28, 2025, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.
Conference Call Details
To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the GeoVax website at geovax.com/investors. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archive of the audio webcast will be available on GeoVax’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Lock/Unlock Feature Now Live in 12 States to Help Safeguard SNAP Benefits
FLORHAM PARK, N.J.–(BUSINESS WIRE)–Jul. 22, 2025– Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, announced the continued deployment of its Electronic Benefits Transfer (EBT) solutions to enhance security and the end-user experience. These enhancements include fraud prevention tools such as intelligent voice systems that detect suspicious calls, technologies enabling the planned move to EBT chip cards and mobile wallet integration, as well as a Conduent feature that locks and unlocks accounts, which is now being used in 12 U.S. states.
The lock/unlock feature enables recipients of government assistance – specifically participants in the Supplemental Nutrition Assistance Program (SNAP) – to lock and unlock their EBT accounts through Conduent’s ConnectEBT mobile app and cardholder portal.
Benefit recipients can lock their card to block all purchases or limit the blocking to purchases outside of their home state, giving them greater control and helping to prevent unauthorized access by fraudsters.
Technology Backed by Conduent’s VeriSight Anti-Fraud Suite
Beyond account locking, Conduent’s VeriSight suite includes an advanced interactive voice response (IVR) system for EBT customer service centers. The system uses behavioral analytics to detect patterns such as excessive calls from a single number, enabling real-time restrictions to prevent suspicious access attempts.
Additionally, users of Conduent’s ConnectEBT app can opt in to receive real-time usage alerts – empowering them to quickly detect and report potentially fraudulent activity.
Future EMV Chip and Mobile Wallet Integration
Meanwhile, Conduent continues to work with several states to prepare for the introduction of SNAP cards with EMV (Europay, Mastercard, and Visa) chip technology, which will further boost card security and reduce fraud risks at points of sale. The company is also poised to support state implementations of mobile wallet functionality, including Apple Pay and Google Pay, to bring added convenience and modernize benefit access.
“With decades of experience in helping state agencies serve residents more effectively, operate more efficiently, and ensure that public aid goes to the intended recipients, our EBT lock-and-unlock feature is one of many solutions Conduent is delivering to combat fraud that threatens taxpayer funds,” said Anna Sever, President, Government Solutions at Conduent. “Our team continues to make progress in implementing important features in more states, while also integrating AI technologies to automate processes, improve efficiency, and reduce costs, while improving service for the people who depend on these critical benefits.”
Conduent is a leading provider of government payment disbursements for federally funded benefit and payment card programs. The company also supports U.S. agencies with end-to-end solutions for healthcare claims processing, eligibility and enrollment, and child support administration.
About Conduent Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.
Forward-Looking Statements This press release, any exhibits or attachments to this release, and other public statements we make may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “expectations,” “in front of us,” “plan,” “intend,” “will,” “aim,” “should,” “could,” “forecast,” “target,” “may,” “continue to,” “looking to continue,” “endeavor,” “if,” “growing,” “projected,” “potential,” “likely,” “see,” “ahead,” “further,” “going forward,” “on the horizon,” “as we progress,” “going to,” “path from here forward,” “think,” “path to deliver,” “from here,” “on track,” “remain” and similar expressions (including the negative and plural forms of such words and phrases), as they relate to us, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact included in this press release or any attachment to this press release are forward-looking statements, including, but not limited to, statements regarding the planned adoption of technology, including all statements made under the first paragraph under the caption “Future EMV Chip and Mobile Wallet Integration” within this release. These statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, many of which are outside of our control, that could cause actual results to differ materially from those expected or implied by such forward-looking statements contained in this press release, any exhibits to this press release and other public statements we make.
Important factors and uncertainties that could cause our actual results to differ materially from those in our forward-looking statements include, but are not limited to those factors that are set forth in the “Risk Factors” section, the “Legal Proceedings” section, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other sections in our 2024 Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission. Any forward-looking statements made by us in this release speak only as of the date on which they are made. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether because of new information, subsequent events or otherwise, except as required by law.
Trademarks Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.
CULVER CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today provided an update on its recently announced stablecoin initiative, establishing Snail Coins LLC, a wholly owned subsidiary of the Company, to serve as the dedicated entity responsible for the issuance, management, and operations of its proprietary USD-backed stablecoin project and other broader digital asset management initiatives.
This move marks a milestone in the Company’s broader stablecoin initiative and broader digital asset management strategy, underscoring the Company’s plans to build a secure, scalable, and transparent digital asset ecosystem.
The stablecoin project is aimed at delivering a secure, regulated, and scalable solution that addresses current market gaps in digital payments and on-chain financial infrastructure. The recent signing of the GENIUS (Guiding and Establishing National Innovation for U.S. Stablecoins) Act into law — which establishes a federal regulatory framework for USD-backed stablecoins — creates a more uniform regulatory structure for stablecoin and has added momentum to the Company’s exploration of a proprietary stablecoin initiative. The Company believes this new regulatory development will enhance market trust, attract institutional interest, and accelerate the broader adoption of compliant digital financial solutions.
“With the GENIUS Act signed into law, we believe the regulatory landscape is beginning to align with the pace of innovation in digital finance,” said Snail, Inc. co-CEO Hai Shi. “The timing of this development couldn’t be more aligned with our own efforts, as we now establish a dedicated subsidiary for our stablecoin and our broader digital asset management initiatives. We view the formation of Snail Coins LLC as more than a corporate structuring move – it’s the beginning of a strategic commitment to the integrity, success, and vision of the project.”
About Snail, Inc. Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.
Forward-Looking Statements This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and in our public filings with the SEC and include, but are not limited to, statements regarding (i) the evaluation and feasibility for introduction of Snail’s own proprietary stablecoin and any future implementation, which will depend on multiple factors, including regulatory considerations, technical readiness, risk assessments and strategic alignment with Snail’s core business, and (ii) Snail’s belief that the GENIUS Act will enhance market trust, attract institutional interest, and accelerate the broader adoption of compliant digital financial solutions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company’s Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
Disclaimer: This press release does not constitute an offer, sale or solicitation of an offer to buy any digital asset or security. The Company has not committed to a specific launch timeline or use case deployment. Any future implementation will depend on multiple factors, including regulatory considerations, technical readiness, risk assessments and strategic alignment with Snail’s core business. Snail may determine at any time to abandon its current intent to explore the issuance of a proprietary US dollar-backed stablecoin.
Investor Contact: John Yi and Steven Shinmachi Gateway Group, Inc. 949-574-3860 SNAL@gateway-grp.com
BATAVIA, N.Y.–(BUSINESS WIRE)– Graham Corporation (NYSE: GHM), a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the Defense, Energy & Process, and Space industries, announced that it will release its first quarter fiscal year 2026 financial results before financial markets open on Tuesday, August 5, 2025.
The Company will host a conference call and webcast to review its financial and operating results, strategy, and outlook. A question-and-answer session will follow.
First Quarter Fiscal Year 2026 Financial Results Conference Call
Tuesday, August 5, 2025 11:00 a.m. Eastern Time Phone: (412) 317-5195 Internet webcast link and accompanying slide presentation: ir.grahamcorp.com
A telephonic replay will be available from 3:00 p.m. ET on the day of the teleconference through Tuesday, August 12, 2025. To listen to the archived call, dial (412) 317-6671 and enter conference ID number 10201479 or access the webcast replay via the Company’s website at ir.grahamcorp.com, where a transcript will also be posted once available.
ABOUT GRAHAM CORPORATION
Graham is a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the Defense, Energy & Process, and Space, industries. Graham Corporation and its family of global brands are built upon world-renowned engineering expertise in vacuum and heat transfer, cryogenic pumps and turbomachinery technologies, as well as its responsive and flexible service and the unsurpassed quality customers have come to expect from the Company’s products and systems. Graham routinely posts news and other important information on its website, grahamcorp.com, where additional information on Graham Corporation and its businesses can be found.
Key Points: – Gold prices remain strong as investors seek stability in volatile markets. – Precious metals and rare earths are gaining renewed interest as geopolitical and economic uncertainty rises. – Small-cap mining and metals companies may offer overlooked upside for risk-conscious investors.
With market volatility back in the headlines and rate cuts on hold, one asset class is quietly shining brighter than the rest: gold. The precious metal has extended its multi-month rally, continuing to hit near-record highs in 2025 as investors worldwide look for safer stores of value.
But this isn’t just about jewelry or bullion. What’s developing beneath the surface is a broader shift in capital flows — away from high-growth risk plays and into hard assets with intrinsic value. That includes not only gold and silver, but also rare earth metals, which are essential to everything from electric vehicles to semiconductors and military tech.
For middle market and small-cap investors, this could mark a key turning point.
Historically, gold performs well during periods of economic instability, inflationary pressure, and geopolitical stress — all conditions currently in play. With inflation proving sticky, central banks cautious on cuts, and conflict hotspots simmering, it’s no surprise institutional and retail investors alike are allocating more to precious metals.
Meanwhile, silver — often seen as gold’s more volatile cousin — has also begun to rally. With industrial use cases tied to clean energy, solar, and advanced tech manufacturing, silver offers a dual benefit: monetary safety and industrial upside.
But perhaps most interesting for middle-market investors is the renewed focus on rare earths — a segment often overlooked but increasingly critical in a tech-dependent world. These niche metals, such as neodymium, dysprosium, and praseodymium, are essential to magnets, batteries, and defense systems. With global supply chains still fragile and China dominating production, the U.S. and its allies are looking to diversify supply — and that puts smaller mining firms in the spotlight.
Companies in the junior mining and exploration space — many trading at micro- and small-cap valuations — could stand to benefit the most. While they carry exploration risk, the potential for outsized returns and strategic partnerships is drawing attention from institutional funds, especially those focused on ESG and supply chain security.
Gold’s continued rise isn’t just a price story — it’s a signal. A signal that investors are recalibrating their portfolios toward resilience, scarcity, and real-world utility.
For investors navigating uncertain terrain, exposure to precious and rare earth metals — whether through physical assets, ETFs, or small-cap equities — offers a compelling hedge. And with much of the sector still under the radar, now may be an ideal time to explore opportunities before the crowd catches on.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
The Merritt Mill is processing ore. Nicola Mining’s (TSX.V: NIM, OTCQB: HUSIF) 100% owned Merritt Mill in British Columbia recently began milling and processing ore from Talisker Resources Ltd.’s (TSX: TSK, OTCQX: TSKFF) Mustang mine to produce gold and silver concentrate. On May 11, Talisker began trucking material to the Craigmont Mill. The commencement of milling operations marked Nicola’s transition to a long-term production plan and sustained revenue and cash flow generation.
Flow-through financing. Nicola Mining raised gross proceeds of C$2,175,000 with a non-brokered private placement of 4,350,000 units at a price of C$0.50 per unit. Each unit consists of one flow-through common share and one-half of one non-flow-through common share purchase warrant. Each warrant is exercisable at a price of C$0.65 and expires two years from the date of issuance. The financing was oversubscribed by a total of 350,000 units or C$175,000. Proceeds will be used to fund exploration at the company’s New Craigmont Copper Project.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Lithium-metal anodes. Century Lithium announced that Alpha-En Corporation successfully converted Century’s lithium carbonate into battery-grade lithium-metal anodes for use in lithium-ion batteries. The lithium-metal anodes were produced using 99.8% pure lithium carbonate from Century’s Angel Island project and demonstration plant. The sample was converted by Alpha-En into lithium metal using Alpha-En’s patented conversion process.
LFP 18650 battery cells. Earlier in the month, Century announced that First Phosphate Corp. produced commercial-grade lithium iron phosphate (LFP) 18650 battery cells using North American critical minerals, including lithium carbonate sourced from Century’s Angel Island project and demonstration plant, along with high-purity phosphoric acid and iron powder from First Phosphate’s Begin-Lamarche property in Quebec. The LFP 18650 battery cells were assembled for First Phosphate by Ultion Technologies at their pilot facility in Nevada.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Key Points: – Trump says his administration is exploring the removal of capital gains taxes on home sales. – The move could unlock capital, boost housing turnover, and benefit housing-related sectors. – Middle-market and small-cap real estate and home improvement firms could see upside from rising transaction activity.
In a surprising policy hint that could reshape the U.S. housing market, President Donald Trump said Tuesday his administration is “thinking about no tax on capital gains on houses.” The statement, delivered from the Oval Office, comes as part of a broader economic playbook aimed at fueling consumer momentum ahead of the 2026 election cycle.
Currently, profits from home sales are subject to capital gains taxes, though homeowners selling their primary residences can deduct up to $250,000 (single) or $500,000 (married) under existing law. Trump’s proposal — which aligns with a new bill introduced by Rep. Marjorie Taylor Greene — would eliminate capital gains tax altogether on home sales, potentially removing one of the biggest friction points in residential real estate.
For investors — particularly in the middle market and small-cap sectors — the implications could be significant.
Removing capital gains tax on homes could encourage long-time homeowners to sell, freeing up inventory in tight markets and fueling demand for adjacent sectors: real estate brokerages, mortgage services, homebuilders, renovation companies, and material suppliers. Small-cap firms in these industries, which have lagged amid high interest rates and a sluggish housing turnover rate, may find themselves back in favor.
The policy could also revive investor sentiment in the residential property space. With more liquidity available and tax incentives restored, buyers may re-enter the market more aggressively, especially if paired with a future Fed rate cut — something Trump alluded to when he said, “If the Fed would lower the rates, we wouldn’t even have to do that.”
From a strategic standpoint, eliminating taxes on home sales would shift housing from being just a lifestyle decision to a more liquid investment vehicle — benefiting not only homeowners but potentially boosting real estate stocks, REITs, and companies supporting the housing ecosystem.
Critics argue such a move could overheat the housing market or primarily benefit wealthier Americans. However, for investors with an eye on undervalued small-cap plays, this policy could be the catalyst that reopens stalled growth pipelines in sectors tied to home transactions — particularly construction, hardware, lending tech, and residential services.
It also ties into a broader trend: a return to asset-based investing over speculative tech — with hard assets like homes, precious metals, and infrastructure increasingly seen as reliable anchors during fiscal uncertainty.
While the proposal is far from finalized, the conversation alone signals that real estate is back on the national economic agenda — and may offer renewed upside for investors willing to look beyond the large caps.
Key Points: – Opendoor shares surge nearly 95% as retail traders rally behind turnaround potential. – Market buzz fueled by comparisons to Carvana’s 100x rebound. – Rebound renews optimism for small-cap proptech firms navigating post-crisis recovery.
Shares of Opendoor Technologies (Nasdaq: OPEN) have soared nearly 95% in Monday trading, extending a jaw-dropping run that saw the online home-buying platform triple in value last week. The catalyst? A mix of bullish small-cap speculation, retail investor momentum, and echoes of past high-profile recoveries.
The sudden surge began after EMJ Capital’s Eric Jackson revealed his firm had taken a position in Opendoor, citing the potential for a “100-bagger” return — a term used to describe stocks with the potential to return 100 times the original investment. Jackson compared Opendoor’s situation to that of Carvana (CVNA), which went from the brink of collapse in 2023 to becoming one of the market’s biggest comeback stories.
Opendoor, once a darling of the real estate tech boom, had lost nearly 98% of its market cap since peaking at nearly $36 per share in early 2021. It had been teetering on the edge of delisting from the Nasdaq after trading below $1 for over 30 days this year. In a bid to remain listed, the company proposed a reverse stock split in June to artificially lift its share price — but that plan may now be unnecessary.
As of Monday, Opendoor shares had closed above $1 for four consecutive sessions, and were trading above $4 by midday — a potential lifeline to retain its Nasdaq listing and buy time for a true turnaround. This rally, although speculative in nature, brings fresh attention to the broader small-cap property technology (proptech) space.
The momentum gained steam in familiar territory: Reddit’s WallStreetBets community. Traders shared screenshots of their Opendoor positions and praised the stock’s volatility, pushing it deeper into meme stock status. While much of the price action has been driven by speculative enthusiasm, the fundamental hope lies in the company’s expected move into positive EBITDA territory in the coming earnings cycle — which could signal a shift from survival to sustainable growth.
For investors in the small and micro-cap space, Opendoor’s rebound offers a powerful reminder of the volatility — and opportunity — inherent in post-crisis tech sectors. As housing markets stabilize and interest rates gradually ease, companies that can operate leaner and show clear paths to profitability are regaining investor confidence.
This momentum has also put a spotlight on similar small-cap proptech and real estate platforms that are undervalued but show operational potential. While it’s unlikely most will see meme-like surges, Opendoor’s rally highlights a window of opportunity for middle-market investors to identify turnaround plays before institutions catch on.
Whether this rally marks a sustainable turnaround or a speculative detour, one thing is clear: the market is watching, and the appetite for underdog small caps is alive and well.
CHICAGO, July 21, 2025 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL), a diversified manufacturer of railroad freight cars, today announced that it will release its second quarter 2025 financial results on Monday, August 4, 2025, after the market close and host a teleconference to discuss its second quarter 2025 results on the following day. Teleconference details are as follows:
Please note that the webcast is listen-only and webcast participants will not be able to participate in the question and answer portion of the conference call. Interested parties are asked to dial in approximately 10 to 15 minutes prior to the start time of the call.
An audio replay of the conference call will be available beginning at 3:00 p.m. (Eastern Time) on Tuesday, August 5, 2025, until 11:59 p.m. (Eastern Time) on Tuesday, August 19, 2025. To access the replay, please dial (844) 512-2921 or (412) 317-6671. The replay passcode is 13754875. An archived version of the webcast will also be available on the FreightCar America Investor Relations website.
About FreightCar America
FreightCar America, headquartered in Chicago, Illinois, is a leading designer, producer and supplier of railroad freight cars, railcar parts and components. We also specialize in railcar repairs, complete railcar rebody services and railcar conversions that repurpose idled rail assets back into revenue service. Since 1901, our customers have trusted us to build quality railcars that are critical to economic growth and instrumental to the North American supply chain. To learn more about FreightCar America, visit www.freightcaramerica.com.
NEW YORK, July 21, 2025 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO):
WHAT:
Travelzoo, the club for travel enthusiasts, will host a conference call to discuss the Company’s financial results for the second quarter ended June 30, 2025. Travelzoo will issue a press release reporting its results before the market opens on July 23, 2025.
WHEN:
July 23, 2025 at 11:00 AM ET
HOW:
A live webcast of Travelzoo’s Q2 2025 earnings conference call can be accessed at http://ir.travelzoo.com/events-presentations. The webcast will be archived within 2 hours of the end of the call and will be available through the same link.
CONTACT:
Travelzoo Investor Relations
ir@travelzoo.com
About Travelzoo We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travelers. Club Members receive Club Offers personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with thousands of top travel suppliers—our long-standing relationships give us access to irresistible deals.
Key Points: – ARCHIMED to acquire ZimVie Inc. for $19/share, nearly doubling its 90-day average price. – The $730M deal will take ZimVie private, accelerating its dental technology growth. – Positive signal for middle market healthcare investors as valuations rebound.
In a strategic move that underscores growing momentum in middle-market healthcare, ZimVie Inc. (Nasdaq: ZIMV), a leader in dental implant technology, has entered into a definitive agreement to be acquired by healthcare-focused investment firm ARCHIMED. The all-cash transaction values ZimVie at approximately $730 million, or $19.00 per share — nearly double its 90-day volume-weighted average price of $9.57.
For ZimVie shareholders, the nearly 99% premium represents a compelling exit, especially as the company faced headwinds in public markets. The deal will take the Florida-based firm private, offering it the strategic flexibility and financial backing often difficult to realize under the scrutiny of quarterly earnings and shareholder pressure.
The acquisition is expected to close by the end of 2025, pending regulatory and shareholder approvals. Until then, ZimVie will continue to operate independently.
ZimVie has carved out a niche in the global dental implant market, developing and delivering a comprehensive portfolio of restoration products and digital workflow solutions. Its global footprint and innovation in oral health make it a prime example of a middle-market firm with strong fundamentals and potential for accelerated growth under private ownership.
ARCHIMED’s interest aligns with a broader trend: private equity firms are showing renewed appetite for small and mid-cap healthcare players that have proven tech, scalable platforms, and room for international expansion. ARCHIMED, which manages €8 billion across its healthcare-focused funds, has a track record of guiding companies through global scaling, M&A, and innovation cycles.
While this deal removes a promising small-cap from public investor reach, it also sends a positive signal to investors looking to identify the next undervalued gem. ZimVie’s valuation leap shows that quality middle-market healthcare firms can still command significant premiums — and that smart capital is actively hunting in this space.
Notably, ZimVie has entered a 40-day “go-shop” period, during which it can solicit competing bids. Though there’s no guarantee of a superior proposal, this opens the door for additional interest, potentially raising the final sale price — a factor for investors still holding shares.
As healthcare innovation continues to be a resilient sector, especially in medtech and dental care, this deal could be a bellwether. Middle market investors may find increasing value in companies that combine specialized solutions with long-term demand — especially before they’re targeted by institutional buyers.
Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval
ATLANTA, GA – July 21, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious diseases and cancer, today reinforced the strategic and commercial significance of the recent positive Scientific Advice (SA) received from the European Medicines Agency (EMA) for its GEO-MVA vaccine targeting Mpox and smallpox.
The EMA’s feedback indicated that a single Phase 3 immuno-bridging trial—bypassing the need for Phase 1 and 2 studies—may be sufficient to support a Marketing Authorization Application (MAA) under the EU’s centralized procedure. The ability to proceed without Phase 1 and 2 clinical trials substantially reduces development risk and timelines, positioning GeoVax to achieve product commercialization and revenue generation significantly earlier than previously anticipated.
Immuno-bridging studies allow for vaccine approval by the immune response elicited by a candidate vaccine comparable to that of an already approved vaccine. This approach, when accepted by regulatory authorities, can reduce the need for large-scale efficacy trials, thereby reducing development time while maintaining regulatory standards for safety and immunogenicity.
“This EMA guidance is more than a regulatory milestone—it represents a potential commercial inflection point,” said David Dodd, Chairman and CEO of GeoVax. “We now have a clear, expedited path to commercialization in one of the world’s largest vaccine markets. With the Phase 3 trial in operational preparation, we are entering a potential revenue acceleration phase supported by growing global demand, regulatory momentum, and our progressing advanced MVA manufacturing platform.”
Key Investor Highlights:
Expedited Approval Path: EMA confirmed that one Phase 3 immuno-bridging trial—if successful—meets criteria for market authorization in all 27 EU countries.
De-Risked Development: Moving directly to a Phase 3 immuno-bridging trial significantly reduces development timelines, cost, and clinical execution risk.
Market Timing Advantage: EMA guidance coincides with the WHO’s fourth Mpox PHEIC declaration and Clade I outbreaks across multiple continents.
First-Mover Opportunity: GEO-MVA would be the only MVA-based Mpox vaccine alternative to Bavarian Nordic’s Imvanex/Imvamune, addressing global supply constraints and monopolistic risk.
Revenue Visibility: GeoVax expects to initiate its Phase 3 trial in 2H 2026.
Manufacturing Readiness: Current CEF-based production supports near-term supply; transition to AGE1 cell line to enable scalable, cost-efficient output for global procurement.
GeoVax is actively engaging with European regulatory bodies, public health stakeholders, and procurement agencies to advance GEO-MVA access and funding partnerships in support of both public health and commercial goals.
“From an investor perspective, this EMA development potentially shortens our path to revenue generation and significantly enhances our strategic value,” said Dodd. “GeoVax is now on the radar as a viable near-term commercial vaccine company, not just a development-stage biotech.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
